Households' aspirations for rural development through agriculture

K Mausch, D Harris, E Heather, E Jones… - Outlook on …, 2018 - journals.sagepub.com
In sub-Saharan Africa, rural households are the focus of many development efforts and the
transformation of smallholder agriculture is one entry point for this process. Understanding …

[HTML][HTML] Immunogenicity of biosimilars for rheumatic diseases, plaque psoriasis, and inflammatory bowel disease: a review from clinical trials and regulatory …

V Strand, J Gonçalves, TP Hickling, HE Jones… - BioDrugs, 2020 - Springer
The goal of this narrative review was to summarize immunogenicity data of biosimilars or
biosimilar candidates for rheumatic diseases, plaque psoriasis, or inflammatory bowel disease (…

Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non …

…, S Wichuk, M Dougados, HE Jones… - Annals of the …, 2018 - ard.bmj.com
Objective To evaluate the impact on structural lesions observed on MRI in the sacroiliac
joints (SIJ) at 12 weeks in patients with non-radiographic axial spondyloarthritis (nr-axSpA) …

Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control …

…, R Bonin, JF Bukowski, HE Jones… - Annals of the …, 2018 - ard.bmj.com
Objective To compare 2 years of radiographic sacroiliac joint (SIJ) changes in patients with
recent onset axial spondyloarthritis (axSpA) receiving etanercept in a clinical trial (EMBARK) …

Longterm drug survival of tumor necrosis factor inhibitors in patients with rheumatoid arthritis

…, B Vlahos, P Szczypa, M Thakur, HE Jones… - The Journal of …, 2020 - jrheum.org
Objective. To evaluate longterm drug survival (proportion of patients still receiving treatment)
and discontinuation of etanercept (ETN), infliximab (IFX), adalimumab (ADA), certolizumab …

[HTML][HTML] Practical guidance on biosimilars, with a focus on Latin America: what do rheumatologists need to know?

…, C Borlenghi, HE Jones - JCR: Journal of …, 2019 - journals.lww.com
Background/Historical Perspective: Availability of biologic diseasemodifying antirheumatic
drugs (bDMARDs) has improved clinical outcomes in rheumatoid arthritis, but it also …

[PDF][PDF] Does psoriatic axial spondyloarthritis phenotype correlate with imaging morphotype

…, LS Gensler, A Szumski, ME Heather Jones… - Clin Exp …, 2020 - clinexprheumatol.org
… Gensler, MD Annette Szumski, MA Heather E. Jones, RN Xenofon Baraliakos, MD Please
… HE Jones was a Pfizer employee at the time this analysis was conducted and may own …

A Pilot dose‐finding study of etanercept in rheumatoid arthritis

FC Breedveld, HE Jones, K Peifer… - Clinical and …, 2018 - Wiley Online Library
A randomized, parallel‐dose study assessed the pharmacokinetics (PK) and pharmacodynamics
(PD) of etanercept in 61 patients with rheumatoid arthritis (RA) who received doses …

[HTML][HTML] Maintenance of Remission with Etanercept–DMARD Combination Therapy Compared with DMARDs Alone in African and Middle Eastern Patients with Active …

H Bassiouni, CE Spargo, B Vlahos, HE Jones… - Rheumatology and …, 2018 - Springer
Heather E. Jones is an employee of Pfizer and owns stock in Pfizer. Ron Pedersen is an
employee of Pfizer and owns stock in Pfizer. Khalid Shirazy is an employee of Pfizer and owns …

[PDF][PDF] Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin

…, KE Bauer-Rowe, AL Titan, A Salhotra, RE Jones… - Cancer Cell, 2022 - cell.com
Cancer-associated fibroblasts (CAFs) are integral to the solid tumor microenvironment. CAFs
were once thought to be a relatively uniform population of matrix-producing cells, but single…